Notch and cancer: a double-edged sword by Koch, U. & Radtke, F.
Review
Notch and cancer: a double-edged sword
U. Koch and F. Radtke*
The Swiss Institute for Experimental Cancer Research (ISREC), Ecole Polytechnique Fdrale de Lausanne
(EPFL), Chemin des Boveresses 155, 1066 Epalinges (Switzerland), Fax: +41216526933,
e-mail: Freddy.Radtke@isrec.ch
Received 2 April 2007; received after revision 29 June 2007; accepted 2 July 2007
Online First 11 August 2007
Abstract. The highly conserved Notch signaling path-
way plays pleiotropic roles during embryonic devel-
opment and is important for the regulation of self-
renewing tissues. The physiological functions of this
signaling cascade range from stem cell maintenance
and influencing cell fate decisions of barely differ-
entiated progenitor cells, to the induction of terminal
differentiation processes, all of which have been found
to be recapitulated in different forms of cancers.
Although Notch signaling has mostly been associated
with oncogenic and growth-promoting roles, depend-
ing on the tissue type it can also function as a tumor
suppressor.Herewe describe recent findings onNotch
signaling in cancer and tumor angiogenesis, and
highlight some of the therapeutic approaches that
are currently being developed to interfere with tumor
growth and progression.
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The Notch signaling cascade
Notch genes encode evolutionarily conserved trans-
membrane bound receptors that are activated by two
families of distinct but equally conserved transmem-
brane bound ligands [1]. Thus, Notch signaling is
mediated via cell-to-cell contact.Mammals have four
Notch receptors (Notch1–4) and five ligands named
Delta-like (DLL) 1, 3 and 4 (homologues of Delta)
and Jagged1 and 2, which are related to Drosophila
Serrate. Notch receptors are synthesized as single
precursor proteins that are cleaved (at site S1) during
their transport to the cell surface by a furin-like
protease [2, 3]. They are expressed at the cell surface
as heterodimers comprising an extracellular subunit
(NEC), which is linked to a second subunit containing
the extracellular heterodimerization domain fol-
lowed by a transmembrane domain and the cyto-
plasmic region of the receptors (NTM). The extrac-
ellular portions of Notch receptors contain 29–36
epidermal growth factor-like repeats implicated in
ligand binding, followed by three cysteine-rich
LIN12/Notch repeats that prevent ligand-independ-
ent signaling and a C-terminal hydrophobic region
mediating heterodimerization between NEC and NTM
[4]. The intracellular portion of NTM mediates cell
signaling, and contains multiple conserved protein
domains (Fig. 1).
Ligand-receptor interactions between two neighbor-
ing cells activate Notch signaling by the induction of
two successive proteolytic cleavages. The first cleav-
age occurs extracellularly, close to the transmembrane
domain (at site S2) and is mediated by a metal-
loprotease of theADAMfamily [5, 6]. This cleavage is
most likely triggered by a physical tug [7] as the
ligands, together with NEC are subsequently endocy-
tosed by the ligand-expressing cell [8]. A monoubi-* Corresponding author.
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quitination process follows cleavage at the S2 site and
eventually triggers the endocytosis-dependent g-sec-
retase-mediated cleavage within the transmembrane
domain (at the S3 site) [9]. This process liberates the
cytoplasmic domain (NICD), which subsequently
translocates to the nucleus [10, 11]. Once in the
nucleus, NICD heterodimerizes with the transcription
factor CSL (CBF-1 in humans, suppressor of hairless
in Drosophila, Lag-1 in Caenorhabditis elegans, also
known asRBP-J inmice) [12]. In the absence ofNotch
signaling, CSL functions as a transcriptional repressor
by binding several co-repressors [13]. NICD converts
CSL into a transcriptional activator by recruiting and
binding co-activators including Mastermind-like pro-
teins (MAML) [14, 15] and CBP/p300 [16] (Fig. 1).
Among the best-known Notch target genes is the
family of transcription factors known as Hairy en-
hancer of split genes (Hes). Members of this family
often negatively regulate the transcription of genes
such as those of the achete scute gene family that are
involved in neuronal differentiation [17]. The related
HERP (Hes-related repressor protein) transcription
factor family [18], the cell cycle regulator Cdkn1a
[19], cyclin D1 [20], the gene for Notch-regulated
ankyrin repeat protein (Nrarp) [21], Deltex1 [22], the
pre T cell receptor a gene [23], the ubiquitin ligase
SKIP2 [24] and the proto-oncogene c-myc [25, 26]
have all been identified as Notch target genes. This
incomplete list of Notch target genes is likely to be
extended, and appears to be context dependent.
Although the Notch cascade is mechanistically rela-
tively simple, the role of Notch signaling and the
activation of downstream target genes in a given tissue
is often unpredictable. With this outline of the Notch
Figure 1. Notch signaling pathway. Notch receptors are synthesized as single precursor proteins, which are cleaved in the Golgi apparatus
by a Furin-like convertase at site S1. Cleavage at site S1 during receptormaturation generates two non-covalently associated subunits (NEC
andNTM).Notch signaling is initiated through ligandbinding to theEGF-like repeats, which induces a second cleavageat site S2 byADAM-
typemetalloproteases generating a short-lived intermediate NTM. This cleavage is triggered by a physical tug as the ligands, together with
NEC are trans-endocytosed by the ligand-expressing cell. The third cleavage occurs at site S3 within the transmembrane domain and is
mediated by g-secretase, which releases NICD. NICD translocates into the nucleus and binds to the transcription factor CSL. This
interaction leads to transcriptional activation by displacement of corepressors (HDAC, SHARP, CIR and SMRT) and simultaneous
recruitment of coactivators including MAML and CBP/p300. EC, extracellular subunit; HD, heterodimerization domain; TM,
transmembrane domain; NICD, cytoplasmic domain; HDAC, histone-deacetylase; CIR, CBF1-interacting corepressor; SMRT, silencing
mediator of retinoid and thyroid receptors; SHARP, SMRT/HDAC-1-associated repressor protein; MAML, Mastermind-like proteins;
CBP, CREB binding protein; CSL, CBF1 in humans, Suppressor of Hairless in Drosophila and LAG in C. elegans. Structure of NICD:
green rectangle, RAM domain; blue circle, ANK repeats (seven iterated ankyrin-like repeats; red rectangle, TAD (transcriptional
activation domain); yellow rectangle, PEST domain (proline, glutamate, serine and threonine-rich degradation sequence).
Cell.Mol. Life Sci. Vol. 64, 2007 Review Article 2747
signaling pathway the stage is set to discuss its crucial
role in various forms of cancer.
Oncogenic functions of Notch in solid tumors
Notch and breast cancer
The first data describing the oncogenic consequences
of aberrant Notch signaling in solid tumors were
derived from animal studies characterizing a frequent
insertion site, named int3, of the mouse mammary
tumor virus (MMTV) [27]. In contrast to retroviruses
that carry oncogenes, MMTV induces mammary
tumors by insertion into the genome and deregulating
expression of adjacent genes. MMTV-deregulated
genes are therefore referred to as “int” (integration)
genes. The int3 site was later identified as the Notch4
locus [28]. Integration of MMTV in this locus results
in the LTR-driven expression of transcripts that
encode a truncated version of the Notch4 receptor
lacking most of the extracellular domain [29]. Trans-
genic mice expressing this truncated dominant active
form of the Notch4/int3 gene under the control of
mammary-specific regulatory elements confirmed a
causative role of aberrant Notch signaling for the
development of mammary tumors [30–32]. Micro-
array studies recently performed on Notch4/int3-
induced tumors identified high expression levels of
c-kit and PDGFR. Treating these mice with the
tyrosine kinase inhibitor Gleevec (Imatinib mesylate)
resulted in decreased proliferation and angiogenesis,
and in the induction of apoptosis within these
mammary tumors. This indicated an oncogenic role
for c-kit and PDGFRa tyrosine kinases in the context
of int3 signaling [33].
Whether Notch4 plays a genuine role during normal
mammary development is not clear. Gene targeted
mice for Notch4 show normal mammary gland devel-
opment and normal lactation, suggesting that Notch4
is either not required for normal mammary develop-
ment, or that another Notch family member compen-
sates for loss of Notch4 function [21]. The role of
Notch signaling during normal mammary develop-
ment was recently investigated by conditional inacti-
vation of the RBP-J gene (encoding the transcrip-
tional mediator of all Notch receptors) and the Pofut
gene (encoding a fucosyltransferase gene, necessary
for efficient ligand receptor binding). In the absence
of either one of these genes a phenotype was only
observed during pregnancy. The RBP-J-deficient
secretory luminal cells acquired the characteristics of
basal cells, and the myoepithelial cells showed ex-
cessive proliferation, resulting in disorganized alveo-
lar structures. These results led to the interpretation
that physiological Notch signaling during pregnancy
maintains the luminal cell fate and prevents uncon-
trolled proliferation of basal cells [34].
MMTV insertions have also been found in theNotch1
locus, albeit with a lower frequency [35]. These
insertions caused the expression of a truncated
Notch1 protein similar to the case of int3. Transgenic
mice expressing a Notch1-derived NICD under the
control of the MMTV LTR develop noninvasive
lactation-dependent papillary tumors that regress
upon gland involution. However, after additional
pregnancies, invasive tumors start to appear, most
likely through the accumulation of secondary muta-
tions [36]. Comparative expression profile analysis
using microarrays led to the identification of the
proto-oncogene c-myc as a direct target gene of
Notch1-induced mammary tumors [25].
All these results on aberrant Notch signaling and
mouse mammary tumorigenesis lead to the question
of how significant aberrant Notch signaling is for
human breast cancer. To date we have only correlative
evidence for the involvement of Notch signaling in
human breast cancer. Expression studies of NOTCH1
on ductal carcinoma in situ tumors showed positive
NOTCH1 staining in approximately two thirds of the
examined cases [37]. Approximately half of the
NOTCH1-positive tumors were H-ras positive, and
in vitro data suggested that H-ras activity increases
NOTCH1 signaling activity [37]. This seems to be
important for the maintenance of the neoplastic
phenotype in ras-transformed human cells. Interest-
ingly, high levels of NOTCH1 and JAGGED1 ex-
pression correlate with poor survival of breast cancer
patients [38]. Consistent with the murine data sug-
gesting that c-myc is a direct downstream effector of
Notch1, coexpression of NOTCH1 and c-MYC has
been found in a large fraction of examined human
breast cancers [39]. Additional evidence that aberrant
Notch signaling might be of importance for human
breast cancer is derived from studies on Numb, a
negative regulator of the Notch cascade [40, 41].
Approximately 50% of the examined human mam-
mary carcinomas, in particular the more aggressive
forms, and most of the breast cancer cell lines exhibit
loss of Numb expression. This finding correlated
inversely with NICD expression and signaling as
well with tumor grade and cell proliferation [42, 43].
The inverse expression pattern of Numb and Notch
might be caused byNotch negatively regulatingNumb
levels as recently suggested by Chapman and collea-
gues [44]. Although these findings are largely corre-
lative, they strongly suggest that aberrant Notch
signaling might be of great importance in human
breast cancer.
2748 U. Koch and F. Radtke Notch and cancer
Notch and medulloblastoma
Medulloblastoma is the most common malignant
brain tumor in childhood [45]. These primitive
neuroectodermal tumors are thought to arise from
neuronal stem or precursor cells of the ventricular
zone and cerebellar external germinal layer [46].
Medulloblastomas have primarily been associated
with aberrant sonic hedgehog signaling (Shh), which
induces expression of N-MYC [47], a protein fre-
quently overexpressed in these type of tumors [48].
Increased activity of the Shh cascade in medullo-
blastomas was reported to be caused by inactivating
mutations in Patched1 or Suppressor-of-Fused, two
negative regulators of Shh signaling, as well as
activating mutations in the Smoothened gene. Muta-
tions in the Axin and APC genes causing increased
activity of theWnt pathway have also been identified
in some medulloblastomas [49, 50] . Until recently
the Notch pathway was mechanistically not associ-
ated with the development of these tumors. How-
ever, the primitive nature of these tumor cells and the
fact that Notch signaling is involved in the main-
tenance of neural stem and progenitor cells [51, 52]
motivated several groups to investigate the potential
role of Notch in medulloblastoma. Expression stud-
ies using primary medulloblastoma tumor samples
showed increased mRNA expression of NOTCH2
but not of NOTCH1. In 15% of the examined tumors
increased NOTCH2 expression levels were shown to
result fromNOTCH2 gene amplification. Moreover,
increased expression of the target gene Hes1 in
medulloblastomas correlated with a poor patient
survival prognosis [53]. Increased expression of
Notch2 and Hes5 has also been observed in a
medulloblastoma mouse model based on the expres-
sion of a constitutively active form of the Smooth-
ened gene in cerebellar granule neuron precursors
[54]. These results suggest that Shh signaling can
induce Notch signaling. Since Numb has recently
been shown to function as a suppressor of hedgehog
signaling [55] and Notch can negatively regulate
Numb levels [44], it is tempting to speculate that Shh
signaling in medulloblastoma activates the Notch
cascade to escape a Numb-mediated regulatory loop,
which would limit the extent and duration of hedge-
hog signaling.
Impediment of Notch signaling, either using g-secre-
tase inhibitors, soluble Delta ligands or siRNA
approaches resulted in increased apoptosis and a
pronounced reduction of viable cells in medulloblas-
toma cell lines and/or primary tumor cell cultures [53,
54]. Gain-of-function studies using a dominant active
form of Notch2 promoted cell proliferation, soft agar
colony formation and xenograft growth, whereas
forced expression of Notch1 ICD (N1ICD) was
growth inhibitory, suggesting that both Notch recep-
tors exhibit distinct functions [53].
Accumulating evidence supports the concept that
many cancer types harbor rare cell populations with
stem cell-like properties, which are responsible for the
propagation of tumor growth [56, 57].Markers such as
CD133 and side population activity have been used to
identify rare cells in brain tumors that have the unique
ability to form tumor neurospheres and xenografts
[58, 59]. Interestingly, in this context a recent report
shows that pharmacological inhibition of Notch
signaling results in the depletion of a cancer stem
cell-like population characterized by the expression of
CD133+ and side population activity. More impor-
tantly, loss of Notch signaling within this cell popula-
tion inhibited medulloblastoma growth both in vitro
and in in vivo xenografts [60]. Although the results are
very promising, additional genetic loss-of-function
experiments in established tumors need to be per-
formed to confirm that Notch signaling is actually
required for the maintenance of these cancer stem-
like cells.
Notch and colorectal cancer
In the intestine Notch signaling has been shown to be
essential for the maintenance of the crypt compart-
ment. Post-natal gut-specific inactivation of the CSL/
RBP-J gene results in the complete loss of proliferat-
ing transient amplifying (TA) cells followed by their
conversion into mucus-secreting goblet cells [61]. In
reciprocal experiments expression of NICD in the gut
inhibits differentiation of crypt progenitors [62]. The
intestine of these transgenic mice consists mostly of
undifferentiated TA cells. These reciprocal genetic
loss- and gain-of-function data established a gate-
keeper function of Notch for intestinal crypt progen-
itor cells in mice. These conclusions have been
supported by toxicology studies of g-secretase inhib-
itors (GSI), which are currently developed by phar-
maceutical companies to inhibit the protease (g-
secretase) activity of presenilins for treatment of
Alzheimers disease. Rodents treated with GSI
display unforeseen side effects, such as loss of
proliferating TA cells accompanied by goblet cell
metaplasia within the crypt compartment due to
inhibition of Notch signaling [63, 64]. This increase
in goblet cell differentiation at the expense of enter-
ocytes suggests an additional function for the Notch
cascade in lineage specification of enterocytes, which
is in agreement with the phenotype observed in gene
targeted mice for the Hes1 gene showing increased
mucus-secreting and enteroendocrine cells at the
expense of enterocytes [65]. A largely reciprocal
phenotype, characterized by intestines only populated
with enterocytes, is observed in gene-targetedmice for
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Math1, which is transcriptionally repressed by Hes1
[66]. Taken together these results point to at least two
physiological functions for Notch; one is the main-
tenance of proliferating undifferentiated crypt pro-
genitors and the other is to control binary cell fate
decisions of progenitors that will differentiate into
either the adsorptive or secretory lineage.
Another signaling cascade that is also of importance
for the maintenance of the crypt progenitors is the
Wnt pathway. Gut-specific inhibition of Wnt signal-
ing results in the loss of the proliferative crypt
compartment [67], suggesting that both the Notch
and the Wnt cascades are necessary for normal gut
homeostasis.
While the causative role of aberrant Wnt signaling
for the development of colorectal cancer is well
established [68], it is currently less clear whether
Notch signaling might have a similar oncogenic
function in the gut. The fact that gene expression
profiles of crypt cells and colorectal cancer cell lines
appear to be very similar suggest that colorectal
cancer cells represent the transformed counter part
of crypt cells [69]. Since Notch is a gate keeper of
crypt cells, it is likely that Notch and Wnt signaling
occur simultaneously in adenomas and crypt cells.
Indeed, expression of the Notch target geneHes1 has
been observed in adenomas of APCMin mice [61] as
well as in primary human colorectal tumors [70].
Treatment of APCMin mice withGSI partially induces
goblet cell differentiation and reduces proliferation
in such adenomas [61], suggesting that inhibition of
Notch signaling can drive cells out of cycle and
induce differentiation despite active Wnt signaling.
The fact that not all of the adenoma cells can be
differentiated might indicate that only early tumor
stages are responsive to GSI, while later stages
become resistant. Nevertheless, primary colorectal
tumor samples and some colorectal cancer cell lines
seem to express Hes1, suggesting that Notch target
gene expression could be maintained through Notch
signaling-independent mechanisms. Indeed, a recent
report shows that Hes1 expression in colorectal
tumor samples can be maintained through IKK
activity via a chromatin-modifying mechanism. Im-
portantly, pharmacological inhibition or expression
of a dominant negative form of IKKa resulted in
Notch target gene repression, which correlated with
reduced tumor size in colorectal cancer xenografts
[70]. These results indicate that maintenance of
Notch target gene expression is of importance for
tumor cell growth and can occur independently of
Notch receptor signaling. This could explain, why
only some adenoma cells are responsive to GSI.
Further genetic loss- and gain-of-function ap-
proaches for Notch signaling molecules and/or target
genes (such as Hes genes) need to be performed to
show that Notch signaling is indeed important for the
development or maintenance of colorectal tumors.
Notch and pancreatic cancer
An early feature of human pancreatic cancers is that
they change their epithelial differentiation program.
Many of the changes (including activation of the
Notch cascade) documented in pathological situations
are also observed during normal embryonic develop-
ment of the pancreas. Notch signaling has been shown
to play an important role during embryonic pancreas
development maintaining an undifferentiated precur-
sor cell type [65, 71, 72]. Notch receptors, ligands and
downstream targets such asHes1were found to be up-
regulated in pre-neoplastic lesions as well as in
invasive pancreatic cancers in humans and mice
[73–75], suggesting that Notch signaling in pancreatic
cancers might be an early event leading to the
accumulation of undifferentiated precursor cells.
This notion was confirmed in explant cultures of
adult mouse pancreas in which forced N1ICD ex-
pression induced a metaplastic conversion from an
acinar cell-predominant epithelium to a ductal cell-
predominant epithelium [73]. Transforming growth
factor-a (TGF-a)-induced EGF receptor signaling is
frequently found in pancreatic cancers [76]. Trans-
genic overexpression of TGF-a also results in acinar-
ductal metaplasia, and correlated with increased
Notch signaling. Interestingly, TGF-a-induced meta-
plasia was abolished by pharmacological blockage of
Notch signaling, indicating that Notch mediates TGF-
a-induced changes in epithelial differentiation during
early pancreatic tumorigenesis [73]. It is likely that
elevatedNotch signaling levels in the pancreas are not
sufficient to generate neoplastic lesions, but it appears
to be sufficient to generate immature pre-neoplastic
lesions susceptible to additional mutations, which
eventually might lead to the development of invasive
ductal carcinoma.
Notch and melanoma
Melanomas are highly aggressive tumors, which
originate from melanocytes deficient in growth con-
trol signals. Melanoma development and progression
can be classified into several steps: (1) acquired and
congenital nevi with normal melanocytes; (2) dys-
plastic nevi with atypic structure; (3) non-tumorigenic
primary melanoma without metastatic competence
(also known as radial growth phase); (4) tumorigenic
primary melanoma with competence for metastasis
(also known as vertical growth phase); and (5)
metastatic melanoma [77]. Once melanomas start to
metastasize they become refractory to conventional
cancer therapy and have a mostly fatal outcome.
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Multiple aberrations due to inactivating and/or acti-
vating mutations in many signaling pathways have
been found in melanoma, including loss of p16INK4a
expression, which correlates with the invasive stage of
melanoma progression [78, 79], activating mutations
in B-raf [80] and N-ras [81], constitutive FGF-
receptor signaling [82] and dysregulated Wnt signal-
ing [83, 84].
Global gene expression profiling and immunohisto-
chemistry revealing the expression of multiple Notch
receptors and ligands in primary lesions of human
malignant melanomas have extended the list of
possible pathways involved in melanoma develop-
ment [85–88]. Subsequent studies on established
melanoma cell lines showed that blocking Notch
signaling pharmacologically could have growth sup-
pressive effects. However, constitutive activation of
Notch promotes growth and survival and in certain
experimental settings lungmetastases inmice [88, 89].
Forced expression of Notch signaling in particular
seems to promote phase four of melanoma, while it
has little effect on already metastatic melanoma cells.
The oncogenic function of Notch signaling within
these cell lines was linked to increased b-catenin-
mediated signaling [88], as well as to increasedMAPK
and AKT signaling [90]. Yet, how Notch signaling
interacts with these pathways in melanoma cells is
currently unclear. Although these studies suggest that
aberrant Notch signaling can influence certain stages
of melanoma, genetic loss-of-function experiments in
established melanoma models need to be performed
in the future to convincingly show that Notch is an
obligate signaling cascade formelanomadevelopment
and/or tumor progression.
Nevertheless, such an essential role for Notch signal-
ing has been shown for normal melanocyte develop-
ment. Melanocyte-specific inactivation of the RBP-J
gene, or simultaneous inactivation of Notch1 and
Notch2 resulted in defective hair pigmentation caused
by loss ofmelanoctye progenitor and/or stem cells due
to apoptosis [91, 92]. Transgenic expression ofHes1 in
Notch signaling-deficient mice efficiently rescues
melanocyte development, suggesting that Notch sig-
naling is important for survival of melanocyte stem or
progenitor cells [91].
Notch and leukemia
Historically, human NOTCH was identified at the
chromosomal breakpoint of a subset of T cell lym-
phoblastic leukemias/lymphomas containing a
t(7;9)(q34;q34.3) chromosomal translocation [93].
The translocation fuses the 3 portion of NOTCH1
to the T cell receptor Jb locus. This results in a
truncated NOTCH1 protein (N1ICD), which is con-
stitutively active and aberrantly expressed [93]. How-
ever, this seminal discovery did not reveal the full
oncogenic potential of the truncated version of
N1ICD. A causative role of Notch1 in T cell lympho-
magenesis was only shown when Pear and colleagues
[94] showed in a murine system that the overexpres-
sion of N1ICD using a retroviral transduction assay of
hematopoietic stem cells led to immature T cell
neoplasms. These and subsequent studies [95, 96]
provided the initial basis for an experimental model
whereby mutations in Notch1 have been analyzed for
their onocgenic potential. Thiswas shortly followedby
studies with transgenic mice expressing dominant-
active forms of Notch1 [22, 97, 98], by the identifica-
tion of additionalNotch1 rearrangements inmice with
radiation-induced thymomas [99], and Notch1 muta-
tions in murine transgenic models of T-ALL [100].
Despite the efficiency of Notch1 in inducing T-ALL in
murine models, it became soon clear that the rare
t(7;9) translocation event could account for only a
minor fraction of T-ALL cases [101]. Ellisen et al. [93]
originally screened 40 T cell leukemia/lymphoma
patient samples and found 4 with the t(7;9) trans-
location. Based on this, an incidence of ~10% was
estimated. However, in subsequent studies, it appears
that <1% of all human T cell leukemias or lympho-
mas contain this translocation [101]. However, more
importantly, aberrant Notch signaling was subse-
quently found in several human leukemias and
lymphomas that lacked genomic rearrangements
[102–104], signifying that upregulatedNotch signaling
might have a common role in human leukemogenesis.
Jundt et al. [102] found high levels of NOTCH1
protein expression in 12 T cell anaplastic large cell
lymphoma (ALCL) samples as compared to B cell
lymphomas, and high levels of cleaved (activated)
NOTCH1 were seen in 2 human ALCL-derived cell
lines, compared to normal T cells. Furthermore,
NOTCH3 was consistently expressed in a sample of
30 human T cell acute leukemias, and dramatically
reduced levels were seen at clinical remission [103].
Interestingly, in T-ALL,Notch-3 is associated with the
expression of its target gene, HES1, and of the gene
encoding pTa [103]. Expression of these three genes is
normally limited to thymocytes and none is usually
expressed in normal mature peripheral T cells. Thus, a
T-ALL signature, resulting from the combined ex-
pression of NOTCH3, pTa and HES1, characterizes
the active and relapsing disease. Intriguingly, in a
study designed to identify NOTCH-1 downstream
targets in T-ALL cells, NOTCH3was one of the genes
up-regulated by NOTCH1 in human T-ALL cell lines
[26]. This could actually suggest that a combination of
N1ICD and N3ICDmay be important in the develop-
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ment of T cell leukemia. N3ICD could possibly
function by activatingNF-kB via its recently described
effect on IKKa [105]. Although these observations do
not establish a causal role for Notch in these T cell
malignancies, they suggest the possibility that up-
regulation of Notch may play a role in more than the
small subset of lymphomas that have the t(7;9)
translocation. More compelling evidence was brought
about by a study published from the laboratory of
Aifantis [106]. They analyzed the gene expression
profile of primary hematopoietic stem and lympho-
cyte progenitor cells, as these are the cell populations
where random Notch1 activating mutations initially
occur. The analysis revealed that a panel of signifi-
cantly up-regulated genes were components of the
NF-kB pathway and included target genes such as
Nfkb2, Relb, Nfkbia, Bcl2a1 and Ccr7. A direct link
between the Notch and NF-kB pathway was provided
using N1ICD to induce the activity of NF-kB report-
ers. Dominant negative forms of the MAML1 and
IkBa genes, respectively, could efficiently antagonize
these interactions. Conclusive evidence was provided
in the same study showing that NOTCH1 human T-
ALL derived mutations activate the NF-kB pathway
and that T-ALL cell lines have an activated NF-kB
pathway. Definitive proof for a central role of
NOTCH1 in human T-ALL came from a recent
study identifying somatic activating mutations in the
NOTCH1 receptor independent of the t(7;9) trans-
location, which were detected in more than 50% of
human T-ALL cases [107]. Additionally, they are
found in all previously defined T-ALL subtypes. One
set of mutations destabilizes the Notch heterodimeri-
zation domain (HD) (gain-of-function mutations),
probably facilitating ligand-independent pathway ac-
tivation, whereas mutations that disrupt the intra-
cellular PEST domain might function by increasing
the half-life of transcriptionally active N1ICD [9]. In
contrast to human T-ALL,HDmutations are rare and
insertions/frameshift mutations in the PESTregion of
Notch1 predominate in mouse T-ALL models [100,
108–110]. However, the precise mechanism by which
Notch1 induces T-ALL is not yet fully elucidated.
Several studies published recently have identified
potentialNotch target genes thatmayplay a role in the
oncogenic potential of Notch in the development and/
or maintenance of disease. One of these target genes
may be the E2A transcription factor. Lack of E2A
predisposes mice to T-ALL. Lymphomas developing
in E2A–/– mice were shown to be critically dependent
onNotch signaling, andNotch1 promoted the survival
and proliferation of these cells, in part through the
induction of pTa [110]. Reschly et al. [110] demon-
strated that the T cell lymphomas accumulated
mutations in or near the PEST domain, which
mediates degradation of the active form of Notch1.
Cell cycle-related genes have been identified to be
candidates for Notch target genes in T cell malignan-
cies. Numerous observations have linked Notch
signaling to the cell cycle machinery, which are likely
to correlate with the ability of Notch to function as an
oncogene [94] or tumor suppressor gene [111]. Yet, a
direct interaction between these two molecular path-
ways was first implicated by Sarmento et al. [24],
revealing that the F-box protein, SKP2, serves to
connect Notch1 activationwith p27Kip1 and p21WAF1/Cip1
regulation. Notch activation led to increased degra-
dation of p27Kip1 and p21Cip1 and to enhanced G1-S
transition. Although the work was done in non-
transformed cell lines, it is possible that the capacity
of Notch to induce SKP2 and to down-regulate p27Kip1
expression may constitute the basis of its oncogenic
potential in T-ALL. Sicinska and co-workers [112]
revealed that mice lacking cyclin D3 are resistant to
leukemogenesis induced by N1ICD. Their results
indicate that cyclin D3 is required for the Notch
oncogenic pathway that signals through pre-TCR, as
well as for the p56LCK pathway that signals down-
stream of the pre-TCR [112]. Specifically, it was
observed that mice lacking cyclin D3 are resistant to
Notch-driven leukemias and show reduced suscepti-
bility to T cell malignancies triggered by p56LCK but
remain fully susceptible to a pre-TCR-independent
oncogenic pathway. In the context of T cell leukemias,
it was demonstrated that suppression of p53 by Notch
is an important event in the development of lympho-
ma and the activation of p53 mediates regression of
disease [88]. Using a tetracycline-inducible model for
N1ICD activation Beverly et al. [113] showed that
Notch suppresses p53 in lymphomagenesis through
repression of the ARF-mdm2-p53 tumor surveillance
network. Although inactivation of the N1ICD trans-
gene leads to tumor regression, 100% of the mice
relapse within 6 weeks. Interestingly, the Notch trans-
gene is reactivated in a majority of the relapsed
tumors, indicating that there is a strong selective
pressure to reacquire Notch activity. N1ICD has also
been shown to directly repress p53 through an mdm2-
independent pathway, by inhibiting its activating
phosphorylations as well as nuclear localization.
Blockage of p53 by N1ICD mainly occurred through
the mammalian target of rapamycin (mTOR) using
phosphatidylinositol 3-kinase (PI3K)-Akt/protein
kinase B (PKB) pathway as the mTOR inhibitor
rapamycin abrogated N1ICD inhibition of p53 [114].
Another recent study also implicated several proteins
in the mTOR pathway as targets of Notch signaling
[74]. The mTOR pathway received activating signals
from Notch and the simultaneous blockade of the
mTOR and Notch pathway with small molecule
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inhibitors resulted in synergistic suppression of T-
ALL growth. One target gene that seems to be
partially responsible for these effects is c-MYC, a
recently described NOTCH1 transcriptional target.
Enforced expression of c-myc can fully rescue
mTOR effectors from Notch withdrawal in a subset
of T-ALL cell lines. This finding implicates c-myc as
an intermediary that connects Notch to mTOR.
Although c-myc was already earlier identified as a
possible Notch target in hematopoietic stem cells
[115] linking Notch responsiveness to a 200-bp
element lying immediately 5 of the c-myc transcrip-
tional start site, neither a direct association of Notch
with this site nor its functional importance was
revealed. Recently, several groups published data
placing c-MYC as a direct downstream target of
NOTCH1 that maintains growth of T-ALL cells.
Weng and colleagues [26] used T-ALL cell lines that
are susceptible to GSI and probed for genes regu-
lated by NOTCH1 using gene expression profiling.
Among the potential target genes identified were
many known Notch targets such as Hes-1, Hey1 and
Deltex.However, c-MYCwas additionally identified.
c-MYC expression was directly correlated to N1ICD
levels and ChIP analysis revealed c-MYC to be a
direct target of NOTCH1. In a similar approach
Palomero et al. [116] also identified NOTCH1 as a
direct regulator of cell growth in human T-ALL cell
lines and placed c-MYC as an immediate target gene
regulated by NOTCH1 in T-ALL, highlighting the
importance of this interaction in the pathogenesis of
human cancer. They were able to elegantly show that
the interaction of NOTCH1 and c-MYC is composed
of a feed-forward-loop regulatory motif controlling
leukemic cell growth. To specifically identify N1ICD
target genes in mouse T cell leukemia, doxycycline-
regulated N1ICD T-ALL cell lines were developed
[117]. Several known Notch1 target genes and
signaling pathways were induced, and consistent
with the above studies c-mycwas again identified as a
direct Notch1 target gene in mouse leukemic cells.
These data provide compelling evidence that c-myc is
also a critical downstream effector of Notch in the
development of T cell leukemia. The existence of a
direct link between Notch and c-myc in T-ALL cell
lines and normal thymocytes has therapeutic as well as
basic implications. Most mutated Notch1 receptors
found in T-ALL cells depend on g-secretase to trans-
mit signals [107, 118], and the withdrawal of c-myc
transgene expression cures ~50%ofmice with T-ALL
[119]. That the primary effect of Notch1 signals in T-
ALL cells appears to be on proliferation and metab-
olism, rather than differentiation or survival, suggests
the use of combinatorial therapies of Notch pathway
inhibitors and other therapeutic agents. This could
take the form of agents that also disrupt protein
synthesis through independent mechanisms, or drugs
that target parallel pathways, such as those that
regulate cell survival directly.
The flip side of the coin: Notch as a tumor suppressor
Up to this point, we have exclusively described
growth promoting or oncogenic roles of the Notch
signaling pathway. In tissues in which Notch exhibits
growth promoting functions, its physiological role is
mostly associated with immature progenitor stages
during development or tissue homeostasis. To allow
terminal differentiation of progenitor cells Notch
signaling often has to be down-regulated. However,
instead of maintaining progenitor cells in an undif-
ferentiated state, or influencing their cell fate deci-
sions, in some tissues Notch can also induce differ-
entiation, which is associated with growth suppres-
sion. The best-studied example is the role of Notch in
the skin. In the murine epidermis Notch receptors
and ligand expression is mostly confined to the
suprabasal layers and not found in the less differ-
entiated stem or TA cells [19] . In vitro data from both
human and mouse keratinocytes suggest that Notch
signaling induces differentiation, which is accompa-
nied by cell cycle arrest [19, 120, 121]. In mouse
keratinocytes, but not human keratinocytes, cell
cycle arrest is induced by Notch1-mediated expres-
sion of the cell cycle regulator p21WAF1/Cip1 [19, 122].
Another property of Notch1 activation is the induc-
tion of early differentiation markers including Ker-
atin1/10 and involucrin, and down-modulation of
integrin expression [19]. Conditional inactivation of
signaling components of the Notch cascade, includ-
ing Notch1, RBP-J and Presenilin1 and 2 in mouse
skin results in hyperproliferation of the skin, hair loss
and epidermal cyst formation within less than
1 month [111, 123–125]. Over time, Notch1-deficient
animals develop spontaneous, highly vascularized
basal cell carcinoma-like tumors. This tumor type in
mouse and man is frequently associated with deregu-
lated Shh signaling, and Notch1 deficiency in the
mouse skin leads to increased Gli2 expression, which
is a downstream component of the Shh pathway
[111]. Another pathway that seems to be deregulated
as a consequence of loss of Notch1 signaling in the
skin is the Wnt cascade. Notch1 deficiency results in
increased b-catenin-mediated signaling in hyperpro-
liferative skin and primary tumor lesions, suggesting
that Notch might suppress Wnt signaling in the skin
[111]. Suppression of Wnt signaling by Notch seems
to be mediated indirectly by increasing p21WAF1/Cip1
protein levels that subsequently bind to the Wnt4
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promoter together with the E2F-1 transcription
factor to down-regulate Wnt4 expression [126].
Moreover, classical chemically induced carcinogene-
sis experiments showed that Notch1-deficient skin is
more susceptible to developing skin cancers. As the
carcinogen-induced mutation predominantly affects
the HA-ras gene, it is possible that loss of Notch1
signaling results in cooperative oncogenic effects with
activated ras. This possibility has been confirmed by
showing that Notch1-deficient keratinocytes forced to
express an activated ras gene, form aggressive squ-
amous cell carcinomas (SCC) when injected subcuta-
neously into nude mice, while wild-type cells do not
[111]. A more recent study showed that transgenic
mice expressing a dominant negative form of
MAML1, which inhibits Notch signaling mediated
by all Notch receptors, develop SCC that are associ-
ated with the accumulation of nuclear b-catenin and
cyclin D1 in tumor cells [127]. Since the mouse skin
expresses Notch1 and Notch2, it is conceivable that
the squamous cell phenotype of the tumors is the
result of a complete block of Notch signaling, while
basal cell carcinomas may occur when only Notch1
signaling is abolished. Future investigations will be
necessary to clarify this issue. Taken together, the
genetic mouse studies strongly suggest that Notch
signaling exhibits tumor suppressive functions in the
skin. This leads to the question of whether these
studies are relevant, or indicative for human skin
cancers. Consistent with the genetic data from gene-
manipulated mice is the finding that human basal cell
carcinomas show reduced expression of NOTCH1,
NOTCH2and JAGGED1 [128].Amore recent report
shows reduced expression of NOTCH1, NOTCH2
and HES1 in a panel of human oral and skin SCC cell
lines, as well as in surgically excised SCCs from
patients. Furthermore, suppression of Notch signaling
in primary human keratinocytes that express an
activated form of the ras gene is sufficient to cause
aggressive SCC in xenograft models [129], similar to
the above-mentioned studies with mouse keratino-
cytes [111]. Mechanistically,Notch1 seems to be a p53
target gene, which negatively regulates Rho GTPase
effector genes that have previously been linked to
tumorigenesis [130–132]. Additional work with
human keratinocytes and primary tumor samples
needs to be performed to further clarify the role of
Notch signaling in the human epidermis and skin
cancer lesions. Nevertheless, it seems very likely that
Notch also functions in human skin as tumor a
suppressor.
Other tissues or forms of cancer where Notch signal-
ing is associatedwith growth suppressive functions are
the prostatic epithelium [121], hepatocellular carci-
noma [133], and small cell lung cancer [134, 135].
However, the growth inhibitory role of Notch has
mainly (with the exception of the prostate) been
suggested on the basis of activated Notch1 over-
expression studies. Thus, further experiments are
clearly needed in these tissues or cancer types to
clarify whether Notch indeed has tumor suppressive
functions.
Notch and tumor angiogenesis
As discussed above, Notch has been associated with
both oncosuppressive and oncogenic roles, and Notch
signaling has been shown to play an important part in
various carcinomas. In adults, blood vessels in most
organs are quiescent – except notably, during the
growth of solid tumors, when otherwise specific
embryonic signaling pathways direct new blood ves-
sels to grow around and into the tumor.One important
player in this process is the vascular endothelial
growth factor (VEGF), which is a potent inducer of
angiogenesis both in embryos and in tumors [136,
137]. The other key player involved in the regulation
of embryonic and tumor vessel development is the
family ofNotch signaling components. Several genetic
studies show the importance of Notch signaling in
angiogenesis as a result of gain- or loss-of-function of
Notch signaling components by either promoting or
inhibiting angiogenesis. Mice deficient for a variety of
these components, including Notch1, Notch1/Notch4,
Jagged1, Dll1, Dll4, Hey1/Hey2, and Presenilins (PS1
and PS2) resulted in embryonic lethality with vascular
remodeling defects [138, 139]. Haploinsufficiency of
Dll4 also resulted in embryonic lethality from severe
vascular defects in mice [140]. Remarkably, endothe-
lial cell-specific N4ICD and knockouts of either
Notch1 or Notch1/Notch4 produced similar pheno-
types [141]. This would imply that either excessive up-
or down-regulation of Notch signaling is detrimental
to vascular development, and thus a narrow range of
optimal expression seems to be essential. There is
ample evidence that the relative expression levels of
Notch on adjacent developing cells influence cell fate
decisions, originally shown by a landmarking report of
Heitzler and Simpson [142] in the developing nervous
system of Drosophila. In their studies, wild-type cells
adopted the epidermal fate (the secondary fate) when
neighboring cells expressed lower Notch levels, but
adopted the neural fate (the primary fate) when
neighboring cells expressed higher Notch levels.
Presumably, a feedback loop, such as that observed
in Caenorhabditis elegans development [143], ampli-
fies initial differences in the expression of Notch on
neighboring cells. In the mammalian system elegant
studies revealed that Notch haploinsufficiency result-
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ed in defined cell fate decisions during T cell develop-
ment [144, 145]. Observations by various other groups
revealed haploinsufficiency of Notch receptors and
ligands in a plethora of developing systems [21, 140,
146–149]. However, the key point in terms of vascular
development is that the various Delta/Jagged-Notch
pathway members are absolutely required at early
stages of vascular development [149, 150]. Although
Notch signaling has been shown to be indispensable
during embryonic development [150, 151], recently
several groups have identified the importance of
Notch signaling in tumor angiogenesis. It has been
reported that DLL4 mRNA is up-regulated in the
vasculature of a xenografted human breast carcinoma
cell line, in endogenous human tumors and following
hypoxia [152]. However, the expression of DLL4 is
restricted to certain areas of microvessels suggesting
that there is finely tuned regulation of Notch signaling
during angiogenesis. Patel et al. [153] demonstrated
that DLL4 expression is up-regulated in clear cell
renal cell carcinoma and is correlated with VEGF
expression. Reduction of basal Dll4 levels in endo-
thelial cells by siRNA led to the inhibition of multiple
endothelial functions in vitro including proliferation,
migration, and network formation, implying the
potential role of this pathway in cancer. In a different
study, VEGF induced the expression of NOTCH1 and
DLL4 through the PI3K–Akt pathway in human
arterial endothelial cells [154]. These studies suggest
that pro-angiogenic factors activateNotch signaling to
promote angiogenesis. Wang and colleagues [155]
showed that tumor-associated growth factors stimu-
late the direct interaction between tumor cells and
endothelial cells viamitogen-activating protein kinase
(MAPK) and Notch signaling pathways, promoting
tumor neovascularization and tumor growth in vivo.
They nicely demonstrated that JAGGED1 is highly
expressed in head and neck squamous cell carcinoma
and is induced through the MAPK pathway. The
elevated JAGGED1 expressions levels on tumor cells
triggered Notch activation in neighboring endothelial
cells and promoted network formation. The effect was
abolished through GSI, soluble JAGGED1 treatment
or dominant negative RBP-Jk expression within the
endothelial cells. These studies are inspiring as they
provide the first causal link between Notch signaling
and tumor angiogenesis.
Preliminary results suggest that Notch signaling may
also play a role in breast cancer angiogenesis.
NOTCH3 is highly expressed in the neovasculature
of human breast tumors, suggesting a possible role for
this receptor in blood vessel maintenance [156].
Estrogen-up-regulated JAGGED1 and NOTCH1 ex-
pression in bothMCF7 and endothelial cells promoted
sprouting in endothelial cells [157]. The same study
also showed that NOTCH1-expressing breast cancer
cells induce hypoxia inducible factor-1a (HIF-1a).
Other recent data suggest that HIF-1a binds and
stabilizes activated Notch1, leading to enhanced
Notch signaling and that Notch signaling was required
to maintain an undifferentiated state in stem cells
under hypoxic conditions [158]. It would be interest-
ing to examine the relevance of these findings in tumor
cells and determine if exposing tumor cells or endo-
thelial cells to hypoxic conditions affects N1ICD
transcriptional activity and tumor angiogenesis.
A series of recent landmark papers have yielded a
better insight into Notch function during the forma-
tion of blood vessels in both embryos and tumors
[159–165]. These new studies [164, 165] identify a
novel role for Notch/Dll4 signaling during vascular
development and reveal the mechanism responsible
for the vascular defects that result from reducedNotch
signaling. Of particular interest is the common finding
that inhibition of Notch signaling led to increased
sprouting and branching of blood vessels. However,
the experiments performed by Noguera-Troise et al.
[159] as well as Rigway et al. [160] revealed that the
administration of either neutralizing antibodies
against Dll4, a recombinant form of the Dll4 protein
that had been generated to blockDll4/Notch signaling
or adenoviruses engineered to express Dll4-Fc inhib-
ited the growth of several different solid tumors in
mice. Although blocking of Dll4 increased the sprout-
ing and branching of blood vessels, and led to a
marked elevation in blood-vessel density in the
tumors, assessment of the vascular network in these
tumors revealed that the new vessels functioned
inefficiently and were not connected functionally to
the vascular network of the tumors. This led inadver-
tently to an overall inhibition of tumor growth. These
promising data have unveiled a new drug target for
disrupting tumor angiogenesis (see below for further
discussion).
Therapeutic approaches
This review has highlighted an important role of the
Notch signaling pathway in cancer development.
Although the causative role of activated Notch in
human carcinogenesis has only been demonstrated
explicitly for human NOTCH1 in several cases of T-
ALL, Notch receptors and ligands are often aberrant-
ly expressed in a wide range of cancers and in tumor-
derived cell lines (see above). One approach that
seems suitable is to target components of the Notch
signaling pathway as a relevant option for cancer
treatment. Thus, protein components of the Notch
pathway – including receptor/ligand binding, release
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of NICD, interaction of NICD and specific down-
stream targets, as well as NICD protein stability –may
provide suitable drug targets; some of these are
already available and others are theoretically possible
(Fig. 2).
Various strategies that have beenused to inhibitNotch
signaling aim at receptor ligand interactions. Studies
targeting blood vessel formation employing blocking
agents to Dll4 [159, 160] revealed substantial tumor
growth reduction. Although, anti-Dll4 treatment in-
hibited tumor growth betterwhen combinedwith anti-
VEGF treatment than when administered alone, the
treatment with the Dll4 blockers was still effective
against tumors that did not respond to anti-VEGF
therapies. Thus, anti-Dll4 treatment may provide a
good option for alternative or combinatorial therapy
for solid tumors that are resistant to anti-VEGF. The
findings of Wang and colleagues [155] highlight that
tumor cells express Notch ligands that are able to
stimulate tumor angiogenesis and tumor growth.
Specific interruption of JAGGED1 signaling within
human tumors may provide a potential novel anti-
angiogenic therapy.
Although various other strategies have been used to
inhibit Notch signaling, including antisense Notch
[166], RNA interference [53, 167], soluble receptor
decoys that act by sequestering Notch ligands [166,
168] and dominant negative forms of MAML or CSL
that decrease the transcriptional activation of target
genes [169, 170], they are still far from actual
therapeutic application. In practice, small-molecule
inhibitors of the g-secretase complex (GSI), which
prevent the release of NICD represent the most
immediately promising therapeutic approach in view
of the current capabilities for the delivery of anti-
cancer drugs. These agents simultaneously target all
Notch receptors [171]. Promising results have been
shown in vivo.One such study involved mice carrying
a mutation in the APC tumor suppressor gene. These
mice spontaneously develop intestinal adenomas
overexpressing Notch target genes such as Hes1.
Treatment with GSI down-regulated Hes1 and turned
proliferative adenoma cells into goblet cells [61].
Kaposi sarcoma samples and cell lines markedly
overexpress activated forms of NOTCH1, 2, 4 as
well as Hey1 and Hey2 compared with normal
endothelial cells. GSI treatment reduced Notch sig-
naling and induced apoptosis in Kaposi sarcoma cells
in vitro. In xenograft models of Kaposi sarcoma
tumors, intra-tumoral injection of GSI inhibited
tumor growth by decreasing proliferation and increas-
ing apoptosis [172]. Several different GSI have been
shown to reduce endothelial cell proliferation, tube
formation and microvessel outgrowths in vitro. In
mouse models of human glioblastomas and lung
adenocarcinomas, both highly vascularized tumors,
the GSI DAPT potently reduced tumor growth and
vascularization [173]. However, most promising is a
phase I clinical trial launched for relapsed or refrac-
tory T-ALL patients and advanced breast cancers
(http://www.clinicaltrials.gov/ct/show/
NCT00100152).
Although, there seems to be quite a broad range of
targeting Notch signaling in cancer therapeutics using
GSI, a major challenge is the untoward side effects
associated with these inhibitors, in particular the
cytotoxicity in the gastrointestinal tract [174], which
can be exacerbated by conventional chemotherapeu-
tic drugs. Therefore, balancing efficacy and toxicity of
GSImust be considered in future clinical applications.
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Figure 2. Therapeutic targets in Notch signaling. The Notch
signaling pathway in various cancers can be targeted at various
levels including receptor ligand binding, release of NICD as well as
the coactivator complex. A promising strategy to block receptor
ligand binding employs inhibitory antibodies directed against
Jagged1 or DLL4 [155, 159, 160]. Blocking DLL4 led to dysfunc-
tional neovascularization and inhibition of tumor growth. Themost
promising results have been achieved using small-molecule inhib-
itors of the g-secretase complex (GSI), preventing the release of
NICD [61, 172, 173]. A phase I clinical trial using the GSIMK0752
inhibitor was initiated in 2005 (http://www.clinicaltrials.gov/ct/
show/NCT00100152). The third protein component of the Notch
signaling that may possibly provide a suitable drug target is the
coactivator complex consisting of CSL, MAML and CBP/p300.
Small inhibitory peptides acting as dominant negative forms of
MAML or CLS decrease the transcriptional activation of target
genes [169, 170].
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